{"entity":{"id":"rnk05047","kind":"drug","name":"RNK05047","aka":[],"tldr":"RNK05047 is a targeted protein degrader from Ranok Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for metastatic cancer.","summary":"RNK05047 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Ranok Therapeutics (Hangzhou) Co., Ltd., in metastatic cancer. A targeted protein degrader, as described in the registry record: it tags a cancer-driving protein for destruction by the cell's own disposal system. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of RNK05047","url":"https://clinicaltrials.gov/search?intr=RNK05047"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05487170"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"RNK05047","modality":"Targeted protein degrader","mechanism":"A targeted protein degrader, as described in the registry record: it tags a cancer-driving protein for destruction by the cell's own disposal system.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rnk05047/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"trial":[{"id":"nct05487170","kind":"trial","name":"A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)","route":"/trials/nct05487170/"}]}}